Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Adverse events and psychological impact · Pregnant women who smoke
1 finding from 1 review
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (6 to 12 months) · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (proportion) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (serious adverse events) · children (aged 6 to 11 years) being overweight or obese
The intervention showed no clear difference in adverse events (serious adverse events) (low certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
Adverse events ‐ radiation oesophagitis · patients with oesophageal cancer
Active cancer therapy combined with TCM may leads to lower adverse events ‐ radiation oesophagitis compared with active cancer therapy (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · preventing acute otitis media in children up to 12 years of age
Xylitol showed no clear difference in gastrointestinal‐related adverse events compared with control (moderate certainty).
3 findings from 1 review
RR 1.04 [0.92, 1.16]
1 study · 326 participants
Moderate
RR 1.43 [0.74, 2.75]
3 studies · 1826 participants
Moderate
RR 2.82 [0.61, 13]
1 study · 1277 participants
Moderate
Intervention not reported
Adverse events report of adverse events · patients with treating strongyloides infection
The intervention showed no clear difference in adverse events report of adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events report of adverse events · patients with treating strongyloides infection
The intervention probably leads to lower adverse events report of adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether the intervention changes adverse events Number of adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Incidence of event · people following primary uncemented THA
It is very uncertain whether the intervention changes total adverse events Incidence of event (very low certainty).
1 finding from 1 review
All topical NSAIDs Local adverse events · adults with strains, sprains, or muscle pull
1 finding from 1 review
Adverse events (a count of reported harms or adverse events/experiences over life of study/ · hospitalised patients who have undergone knee replacement surgery
Primary comparison for continuous passive motion (CPM) showed no clear difference in adverse events Counts of adverse events compared with no CPM (low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with moderate NMB (very low certainty).
1 finding from 1 review